Karen Grooms
About Karen Grooms
Karen Grooms is an MSL in Community Oncology at Bristol Myers Squibb with over two decades of experience in oncology, having transitioned from a Registered Nurse to an Adult Nurse Practitioner.
Title
Karen Grooms currently holds the position of Medical Science Liaison (MSL), Community Oncology at Bristol Myers Squibb in the United States. Her role involves engaging with key stakeholders in the oncology community to facilitate the dissemination of critical scientific information.
Company
Karen Grooms is employed by Bristol Myers Squibb, a prominent biopharmaceutical company known for its focus on discovering, developing, and delivering innovative medicines. She has been with the company for over 8 years, initially joining in 2015 as an Immuno-Oncology Clinical Liaison before transitioning to her current role.
Education and Expertise
Karen Grooms has a robust educational background in nursing and advanced practice. She completed her Bachelor of Science in Nursing at DePauw University from 1981 to 1985. She furthered her education at Indiana University, earning a Master of Science in Nursing (MSN) specializing as an Adult Nurse Practitioner from 2008 to 2011. Her expertise encompasses both clinical and community oncology, built over decades of hands-on experience.
Background
Karen Grooms began her nursing career over 35 years ago. She amassed extensive experience as a Registered Nurse at AHN Hematology/Oncology in Indianapolis, where she served for 14 years. She then advanced to the role of Adult Nurse Practitioner at American Health Network Hematology/Oncology, a position she held for 4 years. These roles provided her with comprehensive clinical knowledge and a strong foundation in oncology.
Oncology Experience
With over two decades of experience in oncology, Karen Grooms has proven expertise in both clinical and community settings. Her career progression from Registered Nurse to Adult Nurse Practitioner at AHN Hematology/Oncology highlights her deep understanding of patient care in oncology. At Bristol Myers Squibb, she continues to contribute significantly, demonstrating her commitment to the field.